AAN 2021: Phase II Trial Shows Evobrutinib Has Prolonged Efficacy in Relapsing Multiple Sclerosis
The 75-mg twice-daily dosing schedule was found to be most effective
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.